Patient Name
Age/Gender
MaxID/Lab ID
Ref By

Centre OP/IP No/UHID Collection Date/Time Reporting Date/Time

SIN No.B2B5330868

TEST REQUESTED

POLE gene mutation analysis

METHOD USED

PCR, Sanger sequencing

SAMPLE INFORMATION

FFPE Block (Block No.: SB-2382/24 A , Tumor Content: 70%)

RESULT Mutation Not Detected

Interpretation		
Wild Type	Indicates absence of mutation in both of the alleles	
Heterozygous	Indicates presence of mutation in one of the allele	
Homozygous	Indicates presence of mutation in both of the alleles	

NOTE

- 1. Clinical significance of this variant need to be evaluated by clinician.
- **2.** Genetic Counselling is recommended.
- 3. This is an in-house developed assay.
- 4. The method used is Sanger sequencing.
- 5. POLE Mutations can be detected by the Assay:

POLE variant	CDS Mutation	POLE variant	CDS Mutation
p.P286R	c.857C>G	p.P436L	c.1307C>T
p.V411L	c.1231G>T	p.L424I	c.1270C>A
p.A456P	c.1366G>C	p.M444K	c.1331T>A
p.S297F	c.890C>T	p.S297A	c.889T>G
p.P436R	c.1307C>G	p.A428T	c.1282G>A
p.S459F	c.1376C>T	p.S461L	c.1382C>T
p.A465V	c.1394C>T	p.A426V	c.1277C>T
p.P286S	c.856C>T	p.D275V	c.824A>T
p.L424V	c.1270C>G	p.L424P	c.?
p.T278M	c.833C>T	p.P441L	c.1322C>T

Test Performed at :910 - Max Hospital - Saket M S S H, Press Enclave Road, Mandir Marg, Saket, New Delhi, Delhi 110017 Booking Centre :2504 - D.R.Maternity & Nursing Home, C2/3, Pragati Market, Ashok Vihar II, Delhi, 110052, 7011845207 The authenticity of the report can be verified by scanning the Q R Code on top of the page



Patient Name Age/Gender MaxID/Lab ID Ref By

Centre OP/IP No/UHID Collection Date/Time Reporting Date/Time

SIN No:B2B5139868

COMMENTS

Molecular analysis of endometrial carcinoma has identified four clinically significant molecular subgroups with differing clinical prognoses: POLE mutations, microsatellite instability-high (MSI-H), copy number low, and copy number high. Mutations in the exonuclease domain of POLE have been reported to improve progression-free survival in endometrial cancer.

wit That

(DR ATUL THATAI) Director Molecular & Cytogenomics

つろ

(DR NITIN DAYAL) Prin. Cons. and Head Hematopathology

